ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy

Autor: Joseph J Johnson, Christopher L. Cubitt, Anthony M. Magliocco, Yin Xiong, Ardeshir Hakam, Douglas C. Marchion, Ozlen Saglam, Daryoush Saeed-Vafa, Robert M. Wenham, Carolina Strosberg
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
medicine.medical_specialty
Receptor
ErbB-4
Microarray
endocrine system diseases
Cell Survival
medicine.medical_treatment
Article
Carboplatin
Immunoenzyme Techniques
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Biomarkers
Tumor
Tumor Cells
Cultured
Neoplasm
Humans
Cystadenocarcinoma
Aged
Neoplasm Staging
Cisplatin
Ovarian Neoplasms
Chemotherapy
business.industry
Hematology
General Medicine
medicine.disease
female genital diseases and pregnancy complications
Cystadenocarcinoma
Serous
030104 developmental biology
chemistry
Drug Resistance
Neoplasm
030220 oncology & carcinogenesis
Case-Control Studies
Immunohistochemistry
Female
Ovarian cancer
business
medicine.drug
Zdroj: Cancer Control
ISSN: 1526-2359
Popis: Few data exist on the prognostic and predictive impact of erb-b2 receptor tyrosine kinase 4 (ERBB4) in ovarian cancer. Thus, we evaluated ERBB4 expression by immunohistochemistry in a tumor microarray consisting of 100 ovarian serous carcinoma specimens (50 complete responses [CRs] and 50 incomplete responses [IRs] to platinum-based therapy), 51 normal tissue controls, and 16 ovarian cancer cell lines. H scores were used to evaluate expression and were semiquantitatively classified into low, intermediate, and high categories. Category frequencies were compared between tumor specimens vs controls using an unpaired t test. Among tumors, category frequencies were compared between CR and IR to chemotherapy. Overall survival (OS) was stratified by category. In total, 74 ovarian serous carcinoma samples (32 CRs and 42 IRs), 28 normal controls, and 16 ovarian cancer cell lines were evaluable. High-level ERBB4 expression was observed at a significantly higher frequency in ovarian serous carcinoma compared with normal control tissue. Among tumor specimens, ERBB4 expression was significantly higher for those with an IR to chemotherapy compared with CR (P = .033). OS was inversely correlated with ERBB4 expression levels. Median rates of OS were 18, 22, and 58 months among high-, intermediate-, and low-expression tumors, respectively. Our results indicate that ERBB4 expression by immunohistochemistry may correlate with chemotherapy-resistant ovarian serous carcinoma and shortened OS.
Databáze: OpenAIRE
Externí odkaz: